Adverum Biotechnologies’ (ADVM) “Buy” Rating Reaffirmed at Chardan Capital
Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $33.00 target price on the biotechnology company’s stock. Several other research analysts also recently weighed in on the stock. Royal Bank of Canada dropped their target […]
Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $33.00 target price on the biotechnology company’s stock. Several other research analysts also recently weighed in on the stock. Royal Bank of Canada dropped their target […]
